RU2011149360A - SUBSTITUTED Phenylureas and Phenylamides as Vanilloid Receptor Ligands - Google Patents
SUBSTITUTED Phenylureas and Phenylamides as Vanilloid Receptor Ligands Download PDFInfo
- Publication number
- RU2011149360A RU2011149360A RU2011149360/02A RU2011149360A RU2011149360A RU 2011149360 A RU2011149360 A RU 2011149360A RU 2011149360/02 A RU2011149360/02 A RU 2011149360/02A RU 2011149360 A RU2011149360 A RU 2011149360A RU 2011149360 A RU2011149360 A RU 2011149360A
- Authority
- RU
- Russia
- Prior art keywords
- alkyl
- methyl
- pyrazol
- phenyl
- trifluoromethyl
- Prior art date
Links
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical class NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 title 1
- 102000011040 TRPV Cation Channels Human genes 0.000 title 1
- 108010062740 TRPV Cation Channels Proteins 0.000 title 1
- 239000003446 ligand Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 claims 189
- -1 benzoimidazolyl Chemical group 0.000 claims 115
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 50
- 229920006395 saturated elastomer Polymers 0.000 claims 48
- 125000001424 substituent group Chemical group 0.000 claims 47
- 229910052801 chlorine Inorganic materials 0.000 claims 46
- 229910052794 bromium Inorganic materials 0.000 claims 44
- 229910052731 fluorine Inorganic materials 0.000 claims 44
- 229910052740 iodine Inorganic materials 0.000 claims 42
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 35
- 150000001875 compounds Chemical class 0.000 claims 27
- 229910004013 NO 2 Inorganic materials 0.000 claims 26
- 125000004076 pyridyl group Chemical group 0.000 claims 22
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 21
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 20
- 125000001544 thienyl group Chemical group 0.000 claims 17
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 16
- 125000000623 heterocyclic group Chemical group 0.000 claims 16
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 15
- 125000001072 heteroaryl group Chemical group 0.000 claims 12
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 claims 12
- 229910052799 carbon Inorganic materials 0.000 claims 10
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 10
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 10
- 125000003118 aryl group Chemical group 0.000 claims 9
- 208000002193 Pain Diseases 0.000 claims 8
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 6
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims 6
- 208000027418 Wounds and injury Diseases 0.000 claims 6
- 125000004432 carbon atom Chemical group C* 0.000 claims 6
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 6
- 125000002541 furyl group Chemical group 0.000 claims 6
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 6
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 6
- 208000011117 substance-related disease Diseases 0.000 claims 6
- 229910052717 sulfur Inorganic materials 0.000 claims 6
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 6
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims 5
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 5
- 229910052760 oxygen Inorganic materials 0.000 claims 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 4
- 208000007848 Alcoholism Diseases 0.000 claims 4
- 206010013654 Drug abuse Diseases 0.000 claims 4
- 208000004454 Hyperalgesia Diseases 0.000 claims 4
- 206010061218 Inflammation Diseases 0.000 claims 4
- 208000006011 Stroke Diseases 0.000 claims 4
- 108010025083 TRPV1 receptor Proteins 0.000 claims 4
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 claims 4
- 239000003153 chemical reaction reagent Substances 0.000 claims 4
- 208000010877 cognitive disease Diseases 0.000 claims 4
- 230000008878 coupling Effects 0.000 claims 4
- 238000010168 coupling process Methods 0.000 claims 4
- 238000005859 coupling reaction Methods 0.000 claims 4
- 230000006378 damage Effects 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 210000001508 eye Anatomy 0.000 claims 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 4
- 230000004054 inflammatory process Effects 0.000 claims 4
- 208000014674 injury Diseases 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 230000036407 pain Effects 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 208000017520 skin disease Diseases 0.000 claims 4
- 238000006467 substitution reaction Methods 0.000 claims 4
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims 3
- 125000004914 dipropylamino group Chemical group C(CC)N(CCC)* 0.000 claims 3
- ZBJWWKFMHOAPNS-UHFFFAOYSA-N loretin Chemical group C1=CN=C2C(O)=C(I)C=C(S(O)(=O)=O)C2=C1 ZBJWWKFMHOAPNS-UHFFFAOYSA-N 0.000 claims 3
- 239000012429 reaction media Substances 0.000 claims 3
- RLWGDRLXZSLGHV-UHFFFAOYSA-N 1-[[4-(2-aminoethoxy)-3-methoxyphenyl]methyl]-3-[(4-tert-butylphenyl)methyl]urea Chemical compound C1=C(OCCN)C(OC)=CC(CNC(=O)NCC=2C=CC(=CC=2)C(C)(C)C)=C1 RLWGDRLXZSLGHV-UHFFFAOYSA-N 0.000 claims 2
- OUEKLNJUMVZULZ-UHFFFAOYSA-N 2-[4-(2-aminoethoxy)-3-methoxyphenyl]-n-[3-(3,4-dimethylphenyl)propyl]acetamide;hydron;chloride Chemical compound Cl.C1=C(OCCN)C(OC)=CC(CC(=O)NCCCC=2C=C(C)C(C)=CC=2)=C1 OUEKLNJUMVZULZ-UHFFFAOYSA-N 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000006820 Arthralgia Diseases 0.000 claims 2
- 208000009079 Bronchial Spasm Diseases 0.000 claims 2
- 206010006482 Bronchospasm Diseases 0.000 claims 2
- 208000032841 Bulimia Diseases 0.000 claims 2
- 206010006550 Bulimia nervosa Diseases 0.000 claims 2
- 206010006895 Cachexia Diseases 0.000 claims 2
- 208000001387 Causalgia Diseases 0.000 claims 2
- 206010008190 Cerebrovascular accident Diseases 0.000 claims 2
- 208000000094 Chronic Pain Diseases 0.000 claims 2
- 208000028698 Cognitive impairment Diseases 0.000 claims 2
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 claims 2
- 206010011224 Cough Diseases 0.000 claims 2
- 206010012335 Dependence Diseases 0.000 claims 2
- 206010012735 Diarrhoea Diseases 0.000 claims 2
- 206010052804 Drug tolerance Diseases 0.000 claims 2
- 208000030814 Eating disease Diseases 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- IKYCZSUNGFRBJS-UHFFFAOYSA-N Euphorbia factor RL9 = U(1) = Resiniferatoxin Natural products COC1=CC(O)=CC(CC(=O)OCC=2CC3(O)C(=O)C(C)=CC3C34C(C)CC5(OC(O4)(CC=4C=CC=CC=4)OC5C3C=2)C(C)=C)=C1 IKYCZSUNGFRBJS-UHFFFAOYSA-N 0.000 claims 2
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 2
- 208000009889 Herpes Simplex Diseases 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 208000035154 Hyperesthesia Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 206010020843 Hyperthermia Diseases 0.000 claims 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 2
- 208000026139 Memory disease Diseases 0.000 claims 2
- 208000019695 Migraine disease Diseases 0.000 claims 2
- OPZKBPQVWDSATI-KHPPLWFESA-N N-Vanillyloleamide Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)NCC1=CC=C(O)C(OC)=C1 OPZKBPQVWDSATI-KHPPLWFESA-N 0.000 claims 2
- QVLMCRFQGHWOPM-ZKWNWVNESA-N N-arachidonoyl vanillylamine Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCC1=CC=C(O)C(OC)=C1 QVLMCRFQGHWOPM-ZKWNWVNESA-N 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 208000001132 Osteoporosis Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 206010035664 Pneumonia Diseases 0.000 claims 2
- 208000004880 Polyuria Diseases 0.000 claims 2
- 208000003251 Pruritus Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 208000025747 Rheumatic disease Diseases 0.000 claims 2
- 206010040880 Skin irritation Diseases 0.000 claims 2
- 208000007107 Stomach Ulcer Diseases 0.000 claims 2
- 102100029613 Transient receptor potential cation channel subfamily V member 1 Human genes 0.000 claims 2
- 108050004388 Transient receptor potential cation channel subfamily V member 1 Proteins 0.000 claims 2
- 206010046543 Urinary incontinence Diseases 0.000 claims 2
- 206010047642 Vitiligo Diseases 0.000 claims 2
- 206010052428 Wound Diseases 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 150000007513 acids Chemical class 0.000 claims 2
- 208000005298 acute pain Diseases 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 2
- 206010001584 alcohol abuse Diseases 0.000 claims 2
- 208000025746 alcohol use disease Diseases 0.000 claims 2
- 230000000172 allergic effect Effects 0.000 claims 2
- 206010053552 allodynia Diseases 0.000 claims 2
- 208000022531 anorexia Diseases 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 208000010668 atopic eczema Diseases 0.000 claims 2
- 230000003376 axonal effect Effects 0.000 claims 2
- 229910052796 boron Inorganic materials 0.000 claims 2
- 206010006451 bronchitis Diseases 0.000 claims 2
- 229960002504 capsaicin Drugs 0.000 claims 2
- 235000017663 capsaicin Nutrition 0.000 claims 2
- 210000000748 cardiovascular system Anatomy 0.000 claims 2
- 208000014439 complex regional pain syndrome type 2 Diseases 0.000 claims 2
- 206010061428 decreased appetite Diseases 0.000 claims 2
- 235000014632 disordered eating Nutrition 0.000 claims 2
- 230000035619 diuresis Effects 0.000 claims 2
- 206010013663 drug dependence Diseases 0.000 claims 2
- 208000000718 duodenal ulcer Diseases 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 230000029142 excretion Effects 0.000 claims 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 2
- 208000013403 hyperactivity Diseases 0.000 claims 2
- 230000036031 hyperthermia Effects 0.000 claims 2
- 125000001041 indolyl group Chemical group 0.000 claims 2
- 210000000936 intestine Anatomy 0.000 claims 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 2
- 230000007794 irritation Effects 0.000 claims 2
- 230000007803 itching Effects 0.000 claims 2
- 238000002690 local anesthesia Methods 0.000 claims 2
- 206010027599 migraine Diseases 0.000 claims 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 2
- 125000002757 morpholinyl group Chemical group 0.000 claims 2
- 230000037023 motor activity Effects 0.000 claims 2
- 210000004400 mucous membrane Anatomy 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 210000002850 nasal mucosa Anatomy 0.000 claims 2
- 210000005036 nerve Anatomy 0.000 claims 2
- 208000004296 neuralgia Diseases 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 208000021722 neuropathic pain Diseases 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- OPZKBPQVWDSATI-UHFFFAOYSA-N oleoyl vanillylamide Natural products CCCCCCCCC=CCCCCCCCC(=O)NCC1=CC=C(O)C(OC)=C1 OPZKBPQVWDSATI-UHFFFAOYSA-N 0.000 claims 2
- 229950010717 olvanil Drugs 0.000 claims 2
- 229940005483 opioid analgesics Drugs 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 claims 2
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims 2
- 125000004193 piperazinyl group Chemical group 0.000 claims 2
- 125000003386 piperidinyl group Chemical group 0.000 claims 2
- 229940080818 propionamide Drugs 0.000 claims 2
- DSDNAKHZNJAGHN-UHFFFAOYSA-N resinferatoxin Natural products C1=C(O)C(OC)=CC(CC(=O)OCC=2CC3(O)C(=O)C(C)=CC3C34C(C)CC5(OC(O4)(CC=4C=CC=CC=4)OC5C3C=2)C(C)=C)=C1 DSDNAKHZNJAGHN-UHFFFAOYSA-N 0.000 claims 2
- DSDNAKHZNJAGHN-MXTYGGKSSA-N resiniferatoxin Chemical compound C1=C(O)C(OC)=CC(CC(=O)OCC=2C[C@]3(O)C(=O)C(C)=C[C@H]3[C@@]34[C@H](C)C[C@@]5(O[C@@](O4)(CC=4C=CC=CC=4)O[C@@H]5[C@@H]3C=2)C(C)=C)=C1 DSDNAKHZNJAGHN-MXTYGGKSSA-N 0.000 claims 2
- 229940073454 resiniferatoxin Drugs 0.000 claims 2
- 208000023504 respiratory system disease Diseases 0.000 claims 2
- 210000003491 skin Anatomy 0.000 claims 2
- 230000036556 skin irritation Effects 0.000 claims 2
- 231100000475 skin irritation Toxicity 0.000 claims 2
- 229910052708 sodium Inorganic materials 0.000 claims 2
- 239000011734 sodium Substances 0.000 claims 2
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 2
- 210000003932 urinary bladder Anatomy 0.000 claims 2
- 230000002485 urinary effect Effects 0.000 claims 2
- 208000009935 visceral pain Diseases 0.000 claims 2
- TVNBJANHBBYARZ-UHFFFAOYSA-N 1-(4-anilinophenyl)-3-[[5-tert-butyl-2-(3-chlorophenyl)pyrazol-3-yl]methyl]urea Chemical compound C=1C=CC(Cl)=CC=1N1N=C(C(C)(C)C)C=C1CNC(=O)NC(C=C1)=CC=C1NC1=CC=CC=C1 TVNBJANHBBYARZ-UHFFFAOYSA-N 0.000 claims 1
- UVAKKUOKTZDMPO-UHFFFAOYSA-N 1-(4-bromo-3-fluorophenyl)-3-[[5-tert-butyl-2-(3-chlorophenyl)pyrazol-3-yl]methyl]urea Chemical compound C=1C=CC(Cl)=CC=1N1N=C(C(C)(C)C)C=C1CNC(=O)NC1=CC=C(Br)C(F)=C1 UVAKKUOKTZDMPO-UHFFFAOYSA-N 0.000 claims 1
- KPCZXNHTLREUJC-UHFFFAOYSA-N 1-[[2-(3-chlorophenyl)-5-(trifluoromethyl)pyrazol-3-yl]methyl]-3-(4-cyclopropyl-3-fluorophenyl)urea Chemical compound C=1C=C(C2CC2)C(F)=CC=1NC(=O)NCC1=CC(C(F)(F)F)=NN1C1=CC=CC(Cl)=C1 KPCZXNHTLREUJC-UHFFFAOYSA-N 0.000 claims 1
- DDVCAULHEAIVDR-UHFFFAOYSA-N 1-[[2-(3-chlorophenyl)-5-(trifluoromethyl)pyrazol-3-yl]methyl]-3-[4-(2-cyclopropylethynyl)-3-fluorophenyl]urea Chemical compound C=1C=C(C#CC2CC2)C(F)=CC=1NC(=O)NCC1=CC(C(F)(F)F)=NN1C1=CC=CC(Cl)=C1 DDVCAULHEAIVDR-UHFFFAOYSA-N 0.000 claims 1
- VWZWBUNKCNCFES-UHFFFAOYSA-N 1-[[5-tert-butyl-2-(3-chlorophenyl)pyrazol-3-yl]methyl]-3-(3,5-difluoro-4-methoxyphenyl)urea Chemical compound C1=C(F)C(OC)=C(F)C=C1NC(=O)NCC1=CC(C(C)(C)C)=NN1C1=CC=CC(Cl)=C1 VWZWBUNKCNCFES-UHFFFAOYSA-N 0.000 claims 1
- JABSVEVTTVTPNI-UHFFFAOYSA-N 1-[[5-tert-butyl-2-(3-chlorophenyl)pyrazol-3-yl]methyl]-3-(3,5-difluorophenyl)urea Chemical compound C=1C=CC(Cl)=CC=1N1N=C(C(C)(C)C)C=C1CNC(=O)NC1=CC(F)=CC(F)=C1 JABSVEVTTVTPNI-UHFFFAOYSA-N 0.000 claims 1
- DZAMWZKNIJUCNV-UHFFFAOYSA-N 1-[[5-tert-butyl-2-(3-chlorophenyl)pyrazol-3-yl]methyl]-3-(3-fluoro-4-methylsulfonylphenyl)urea Chemical compound C=1C=CC(Cl)=CC=1N1N=C(C(C)(C)C)C=C1CNC(=O)NC1=CC=C(S(C)(=O)=O)C(F)=C1 DZAMWZKNIJUCNV-UHFFFAOYSA-N 0.000 claims 1
- XNIVUEXEZLCCBZ-UHFFFAOYSA-N 1-[[5-tert-butyl-2-(3-chlorophenyl)pyrazol-3-yl]methyl]-3-(3-fluoro-4-morpholin-4-ylphenyl)urea Chemical compound C=1C=CC(Cl)=CC=1N1N=C(C(C)(C)C)C=C1CNC(=O)NC(C=C1F)=CC=C1N1CCOCC1 XNIVUEXEZLCCBZ-UHFFFAOYSA-N 0.000 claims 1
- AQGBIDFTCXQXAZ-UHFFFAOYSA-N 1-[[5-tert-butyl-2-(3-chlorophenyl)pyrazol-3-yl]methyl]-3-(4-methoxy-3,5-dimethylphenyl)urea Chemical compound C1=C(C)C(OC)=C(C)C=C1NC(=O)NCC1=CC(C(C)(C)C)=NN1C1=CC=CC(Cl)=C1 AQGBIDFTCXQXAZ-UHFFFAOYSA-N 0.000 claims 1
- ORMMDOARHGBRHA-UHFFFAOYSA-N 1-[[5-tert-butyl-2-(3-chlorophenyl)pyrazol-3-yl]methyl]-3-[4-(difluoromethoxy)phenyl]urea Chemical compound C=1C=CC(Cl)=CC=1N1N=C(C(C)(C)C)C=C1CNC(=O)NC1=CC=C(OC(F)F)C=C1 ORMMDOARHGBRHA-UHFFFAOYSA-N 0.000 claims 1
- GBEVXRCIOQIWAA-UHFFFAOYSA-N 1-[[5-tert-butyl-2-(3-chlorophenyl)pyrazol-3-yl]methyl]-3-[4-(trifluoromethyl)phenyl]urea Chemical compound C=1C=CC(Cl)=CC=1N1N=C(C(C)(C)C)C=C1CNC(=O)NC1=CC=C(C(F)(F)F)C=C1 GBEVXRCIOQIWAA-UHFFFAOYSA-N 0.000 claims 1
- HMSXRGACEHJFNH-UHFFFAOYSA-N 1-[[5-tert-butyl-2-(4-fluorophenyl)pyrazol-3-yl]methyl]-3-(3-fluorophenyl)urea Chemical compound C=1C=C(F)C=CC=1N1N=C(C(C)(C)C)C=C1CNC(=O)NC1=CC=CC(F)=C1 HMSXRGACEHJFNH-UHFFFAOYSA-N 0.000 claims 1
- JZILDWCYKQFLGV-UHFFFAOYSA-N 2-(3-fluorophenyl)acetamide Chemical compound NC(=O)CC1=CC=CC(F)=C1 JZILDWCYKQFLGV-UHFFFAOYSA-N 0.000 claims 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- VJONSIPSIMDOAH-UHFFFAOYSA-N 3-[[2-(3-chlorophenyl)-5-(trifluoromethyl)pyrazol-3-yl]methyl]-1-(3-fluorophenyl)-1-methylurea Chemical compound C=1C=CC(F)=CC=1N(C)C(=O)NCC1=CC(C(F)(F)F)=NN1C1=CC=CC(Cl)=C1 VJONSIPSIMDOAH-UHFFFAOYSA-N 0.000 claims 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- FMDMZEMMKAISAJ-UHFFFAOYSA-N 4-[1-[[2-(3-chlorophenyl)-5-(trifluoromethyl)pyrazol-3-yl]methylamino]-1-oxopropan-2-yl]-2-fluoro-n-phenylbenzamide Chemical compound C=1C=C(C(=O)NC=2C=CC=CC=2)C(F)=CC=1C(C)C(=O)NCC1=CC(C(F)(F)F)=NN1C1=CC=CC(Cl)=C1 FMDMZEMMKAISAJ-UHFFFAOYSA-N 0.000 claims 1
- LPSZCUNAQWQFEA-UHFFFAOYSA-N 4-[1-[[2-(3-chlorophenyl)-5-(trifluoromethyl)pyrazol-3-yl]methylamino]-1-oxopropan-2-yl]-2-fluorobenzamide Chemical compound C=1C=C(C(N)=O)C(F)=CC=1C(C)C(=O)NCC1=CC(C(F)(F)F)=NN1C1=CC=CC(Cl)=C1 LPSZCUNAQWQFEA-UHFFFAOYSA-N 0.000 claims 1
- FDYUKCXNOMYNEN-UHFFFAOYSA-N 4-[1-[[2-(3-chlorophenyl)-5-(trifluoromethyl)pyrazol-3-yl]methylamino]-1-oxopropan-2-yl]-n-ethylbenzamide Chemical compound C1=CC(C(=O)NCC)=CC=C1C(C)C(=O)NCC1=CC(C(F)(F)F)=NN1C1=CC=CC(Cl)=C1 FDYUKCXNOMYNEN-UHFFFAOYSA-N 0.000 claims 1
- QILLHTNHGXWDCH-UHFFFAOYSA-N 4-[1-[[2-(3-chlorophenyl)-5-(trifluoromethyl)pyrazol-3-yl]methylamino]-1-oxopropan-2-yl]-n-phenylbenzamide Chemical compound C=1C=C(C(=O)NC=2C=CC=CC=2)C=CC=1C(C)C(=O)NCC1=CC(C(F)(F)F)=NN1C1=CC=CC(Cl)=C1 QILLHTNHGXWDCH-UHFFFAOYSA-N 0.000 claims 1
- LXXKKKUMZIHOGW-UHFFFAOYSA-N 4-[1-[[2-(dipropylamino)-5-(trifluoromethyl)pyrazol-3-yl]methylamino]-1-oxopropan-2-yl]-2-fluorobenzamide Chemical compound CCCN(CCC)N1N=C(C(F)(F)F)C=C1CNC(=O)C(C)C1=CC=C(C(N)=O)C(F)=C1 LXXKKKUMZIHOGW-UHFFFAOYSA-N 0.000 claims 1
- FZKKSICZBAKXFM-UHFFFAOYSA-N 4-[1-[[2-(dipropylamino)-5-(trifluoromethyl)pyrazol-3-yl]methylamino]-1-oxopropan-2-yl]-n-pyridin-2-ylbenzamide Chemical compound CCCN(CCC)N1N=C(C(F)(F)F)C=C1CNC(=O)C(C)C1=CC=C(C(=O)NC=2N=CC=CC=2)C=C1 FZKKSICZBAKXFM-UHFFFAOYSA-N 0.000 claims 1
- SGRFRGTUZFMAEL-UHFFFAOYSA-N 4-[1-[[2-cyclobutyl-5-(trifluoromethyl)-1,2,4-triazol-3-yl]methylamino]-1-oxopropan-2-yl]-2-fluorobenzamide Chemical compound C=1C=C(C(N)=O)C(F)=CC=1C(C)C(=O)NCC1=NC(C(F)(F)F)=NN1C1CCC1 SGRFRGTUZFMAEL-UHFFFAOYSA-N 0.000 claims 1
- OHUYGVRFZPFERB-UHFFFAOYSA-N 4-[1-[[2-cyclohexyl-5-(trifluoromethyl)-1,2,4-triazol-3-yl]methylamino]-1-oxopropan-2-yl]-2-fluorobenzamide Chemical compound C=1C=C(C(N)=O)C(F)=CC=1C(C)C(=O)NCC1=NC(C(F)(F)F)=NN1C1CCCCC1 OHUYGVRFZPFERB-UHFFFAOYSA-N 0.000 claims 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- 150000001204 N-oxides Chemical class 0.000 claims 1
- 125000000066 S-methyl group Chemical group [H]C([H])([H])S* 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000005872 benzooxazolyl group Chemical group 0.000 claims 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 1
- 125000001786 isothiazolyl group Chemical group 0.000 claims 1
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- RKPSUORPLJGACA-UHFFFAOYSA-N n-[[2-(3-chlorophenyl)-5-(trifluoromethyl)pyrazol-3-yl]methyl]-2-(3-fluorophenyl)-2-methylpropanamide Chemical compound C=1C=CC(F)=CC=1C(C)(C)C(=O)NCC1=CC(C(F)(F)F)=NN1C1=CC=CC(Cl)=C1 RKPSUORPLJGACA-UHFFFAOYSA-N 0.000 claims 1
- PONXTZIGKAOXBT-UHFFFAOYSA-N n-[[5-tert-butyl-2-(3-chlorophenyl)pyrazol-3-yl]methyl]-2-[3-fluoro-4-(2-methoxyethoxymethyl)phenyl]propanamide Chemical compound C1=C(F)C(COCCOC)=CC=C1C(C)C(=O)NCC1=CC(C(C)(C)C)=NN1C1=CC=CC(Cl)=C1 PONXTZIGKAOXBT-UHFFFAOYSA-N 0.000 claims 1
- IODORSWUQLRHCE-UHFFFAOYSA-N n-[[5-tert-butyl-2-(3-chlorophenyl)pyrazol-3-yl]methyl]-2-[3-fluoro-4-(methanesulfonamido)phenyl]-2-(4-methylphenyl)acetamide Chemical compound C1=CC(C)=CC=C1C(C=1C=C(F)C(NS(C)(=O)=O)=CC=1)C(=O)NCC1=CC(C(C)(C)C)=NN1C1=CC=CC(Cl)=C1 IODORSWUQLRHCE-UHFFFAOYSA-N 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 claims 1
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 claims 1
- AHWALFGBDFAJAI-UHFFFAOYSA-N phenyl carbonochloridate Chemical compound ClC(=O)OC1=CC=CC=C1 AHWALFGBDFAJAI-UHFFFAOYSA-N 0.000 claims 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000002098 pyridazinyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 125000000547 substituted alkyl group Chemical group 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 1
- 125000003831 tetrazolyl group Chemical group 0.000 claims 1
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000004306 triazinyl group Chemical group 0.000 claims 1
- 125000001425 triazolyl group Chemical group 0.000 claims 1
Claims (14)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17628409P | 2009-05-07 | 2009-05-07 | |
| EP09006237 | 2009-05-07 | ||
| EP09006237.3 | 2009-05-07 | ||
| US61/176,284 | 2009-05-07 | ||
| PCT/EP2010/002786 WO2010127856A1 (en) | 2009-05-07 | 2010-05-06 | Substituted phenyllureas and phenylamides as vanilloid receptor ligands |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2011149360A true RU2011149360A (en) | 2013-06-20 |
| RU2553392C2 RU2553392C2 (en) | 2015-06-10 |
Family
ID=40908456
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2011149360/04A RU2553392C2 (en) | 2009-05-07 | 2010-05-06 | Substituted phenylureas and phenylamides as ligands of vanilloid receptors |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US8592471B2 (en) |
| EP (1) | EP2427435B1 (en) |
| JP (1) | JP5745505B2 (en) |
| KR (1) | KR101746016B1 (en) |
| CN (2) | CN106243037A (en) |
| AR (1) | AR076752A1 (en) |
| AU (1) | AU2010244685B2 (en) |
| BR (1) | BRPI1011043B8 (en) |
| CA (1) | CA2759951C (en) |
| CO (1) | CO6440569A2 (en) |
| EC (1) | ECSP11011433A (en) |
| ES (1) | ES2640257T3 (en) |
| IL (1) | IL215661A (en) |
| MX (1) | MX2011011797A (en) |
| NZ (1) | NZ595759A (en) |
| PE (1) | PE20120374A1 (en) |
| RU (1) | RU2553392C2 (en) |
| TW (1) | TWI491595B (en) |
| WO (1) | WO2010127856A1 (en) |
| ZA (1) | ZA201107706B (en) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110092554A1 (en) * | 2007-11-19 | 2011-04-21 | Richard Chesworth | 1,3,5 tri-subtituted benzenes for treatment of alzheimer's disease and other disorders |
| RU2527177C2 (en) | 2007-12-20 | 2014-08-27 | Энвиво Фармасьютикалз, Инк. | Tetrasubstituted benzenes |
| US8946204B2 (en) * | 2009-05-07 | 2015-02-03 | Gruenenthal Gmbh | Substituted phenylureas and phenylamides as vanilloid receptor ligands |
| EP2316820A1 (en) * | 2009-10-28 | 2011-05-04 | Dompe S.p.A. | 2-aryl-propionamide derivatives useful as bradykinin receptor antagonists and pharmaceutical compositions containing them |
| JP2013542231A (en) * | 2010-11-10 | 2013-11-21 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | Substituted bicyclic aromatic carboxamide derivatives and urea derivatives as vanilloid receptor ligands |
| BR112014001880A2 (en) | 2011-07-26 | 2017-02-21 | Gruenenthal Gmbh | substituted heteroaromatic pyrazole-containing carboxamide and urea derivatives as vanyloid receptor ligands |
| JP2014521617A (en) | 2011-07-26 | 2014-08-28 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | Substituted bicyclic aromatic carboxamides and urea derivatives as vanilloid receptor ligands |
| EP2776424A1 (en) | 2011-11-09 | 2014-09-17 | Grünenthal GmbH | Substituted pyrazolyl-based carboxamide and urea derivatives bearing a phenyl moiety substituted with an n-cyclic group as vanilloid receptor ligands |
| BR112014011108A2 (en) | 2011-11-09 | 2017-05-16 | Gruenenthal Gmbh | substituted pyrazolyl-based carboxamide and urea derivatives bearing a phenyl moiety substituted with a group containing so2 as vanyloid receptor ligands |
| HK1202116A1 (en) * | 2011-11-09 | 2015-09-18 | Grünenthal GmbH | Substituted pyrazolyl-based carboxamide and urea derivatives bearing a phenyl moiety substituted with an n-containing group as vanilloid receptor ligands |
| KR20140091042A (en) | 2011-11-09 | 2014-07-18 | 그뤼넨탈 게엠베하 | Substituted pyrazolyl-based carboxamide and urea derivatives bearing a phenyl moiety substituted with a co-containing group as vanilloid receptor ligands |
| HK1201839A1 (en) | 2011-11-09 | 2015-09-11 | Grünenthal GmbH | Substituted pyrazolyl-based carboxamide and urea derivatives bearing a phenyl moiety substituted with an o-containing group as vanilloid receptor ligands |
| FR2998892B1 (en) * | 2012-12-04 | 2015-01-02 | Pf Medicament | AMINOCYCLOBUTANE DERIVATIVES, PROCESS FOR PREPARING THEM AND THEIR USE AS MEDICAMENTS |
| WO2014122083A1 (en) | 2013-02-06 | 2014-08-14 | Bayer Cropscience Ag | Halogen-substituted pyrazol derivatives as pest-control agents |
| KR20160104065A (en) | 2014-01-03 | 2016-09-02 | 바이엘 애니멀 헬스 게엠베하 | Novel pyrazolyl-heteroarylamides as pesticides |
| CN103787839B (en) * | 2014-01-21 | 2015-12-02 | 苏州昊帆生物科技有限公司 | The method of synthesis 2,3,4,5,6-Pentafluorophenol |
| EP3224252B1 (en) * | 2014-11-24 | 2019-01-09 | Medifron Dbt Inc. | Substituted oxazole- and thiazole-based carboxamide and urea derivatives as vanilloid receptor ligands ii |
| WO2018015411A1 (en) * | 2016-07-20 | 2018-01-25 | F. Hoffmann-La Roche Ag | Sulfonylcycloalkyl carboxamide compounds as trpa1 modulators |
| CN109020808B (en) * | 2017-06-12 | 2021-07-06 | 浙江九洲药业股份有限公司 | A kind of preparation method of substituted phenylacetic acid derivative |
| ES2965494T3 (en) * | 2018-04-12 | 2024-04-15 | Bayer Ag | Derivatives of N-(cyclopropylmethyl)-5-(methylsulfonyl)-n-{1-[1-(pyrimidin-2-yl)-1H-1,2,4-triazol-5-yl]ethyl}benzamide and the corresponding pyridine-carboxamide derivatives as pesticides |
| CN108785676A (en) * | 2018-06-25 | 2018-11-13 | 青岛大学 | TRPV1 is to MAP habituation regulating and controlling effects |
| CN111257444A (en) * | 2020-01-20 | 2020-06-09 | 中国医科大学附属第一医院 | A kind of anti-Alzheimer's disease candidate compound blood concentration detection method |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6979686B1 (en) * | 2001-12-07 | 2005-12-27 | Pharmacia Corporation | Substituted pyrazoles as p38 kinase inhibitors |
| EP1020447A4 (en) * | 1997-09-11 | 2000-11-15 | Nissan Chemical Ind Ltd | Pyrazole compounds and plant disease control agent |
| HK1056164B (en) * | 2000-03-24 | 2013-06-21 | Euro-Celtique S.A. | Aryl substituted pyrazoles, triazoles and tetrazoles as sodium channel blocker |
| JP2004525071A (en) | 2000-07-20 | 2004-08-19 | ニューロジェン コーポレイション | Capsaicin receptor ligand |
| GB0206876D0 (en) | 2002-03-22 | 2002-05-01 | Merck Sharp & Dohme | Therapeutic agents |
| US7135575B2 (en) * | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| EP1643960A2 (en) * | 2003-07-02 | 2006-04-12 | Merck & Co., Inc. | Arylsulfonamide derivatives |
| EP1940821B1 (en) | 2005-10-19 | 2013-03-20 | Grünenthal GmbH | Novel vanilloid receptor ligands and their use for producing medicaments |
| US20110195110A1 (en) * | 2005-12-01 | 2011-08-11 | Roger Smith | Urea compounds useful in the treatment of cancer |
| BRPI0713187A2 (en) * | 2006-07-20 | 2012-10-16 | Mehmet Kahraman | method of inhibiting rho kinase, method of treating rho kinase mediated disease, compound and pharmaceutical composition |
| ATE509925T1 (en) * | 2006-11-17 | 2011-06-15 | Pfizer | SUBSTITUTED BICYCLOCARBONIC ACID AMIDE COMPOUNDS |
| TW200833663A (en) * | 2006-12-21 | 2008-08-16 | Astrazeneca Ab | Therapeutic agents |
| DE102007018149A1 (en) | 2007-04-16 | 2008-10-23 | Grünenthal GmbH | Novel vanilloid receptor ligands and their use in the preparation of medicines |
| CA2683461A1 (en) * | 2007-04-16 | 2008-10-23 | Gruenenthal Gmbh | Novel vanilloid receptor ligands and the use thereof for the production of pharmaceuticals |
| WO2008137102A2 (en) | 2007-05-04 | 2008-11-13 | Torreypines Therapeutics, Inc. | Methods of modulating amyloid beta and compounds useful therefor |
| KR20100031639A (en) * | 2007-07-09 | 2010-03-23 | 아스트라제네카 아베 | Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases |
| JP2008251019A (en) | 2008-04-18 | 2008-10-16 | Dainippon Printing Co Ltd | Membership procedure device and contactless IC tag distribution method |
| JP2010083763A (en) * | 2008-09-29 | 2010-04-15 | Mitsui Chemicals Inc | Pyrazole derivative, method of producing the same, and bactericide |
| WO2010108187A2 (en) | 2009-03-20 | 2010-09-23 | Brandeis University | Compounds and methods for treating mammalian gastrointestinal microbial infections |
| US8334315B2 (en) * | 2009-05-07 | 2012-12-18 | Gruenenthal Gmbh | Substituted aromatic carboxamide and urea derivatives as vanilloid receptor ligands |
-
2010
- 2010-05-06 ES ES10720271.5T patent/ES2640257T3/en active Active
- 2010-05-06 KR KR1020117029221A patent/KR101746016B1/en active Active
- 2010-05-06 US US12/775,235 patent/US8592471B2/en active Active
- 2010-05-06 CN CN201610612973.XA patent/CN106243037A/en active Pending
- 2010-05-06 BR BRPI1011043A patent/BRPI1011043B8/en active IP Right Grant
- 2010-05-06 AU AU2010244685A patent/AU2010244685B2/en active Active
- 2010-05-06 NZ NZ595759A patent/NZ595759A/en not_active IP Right Cessation
- 2010-05-06 EP EP10720271.5A patent/EP2427435B1/en active Active
- 2010-05-06 AR ARP100101547A patent/AR076752A1/en unknown
- 2010-05-06 CN CN2010800196125A patent/CN102428071A/en active Pending
- 2010-05-06 TW TW099114462A patent/TWI491595B/en not_active IP Right Cessation
- 2010-05-06 RU RU2011149360/04A patent/RU2553392C2/en not_active IP Right Cessation
- 2010-05-06 CA CA2759951A patent/CA2759951C/en not_active Expired - Fee Related
- 2010-05-06 WO PCT/EP2010/002786 patent/WO2010127856A1/en not_active Ceased
- 2010-05-06 PE PE2011001916A patent/PE20120374A1/en not_active Application Discontinuation
- 2010-05-06 JP JP2012508951A patent/JP5745505B2/en active Active
- 2010-05-06 MX MX2011011797A patent/MX2011011797A/en not_active Application Discontinuation
-
2011
- 2011-10-07 CO CO11133069A patent/CO6440569A2/en not_active Application Discontinuation
- 2011-10-10 IL IL215661A patent/IL215661A/en not_active IP Right Cessation
- 2011-10-20 ZA ZA2011/07706A patent/ZA201107706B/en unknown
- 2011-11-01 EC EC2011011433A patent/ECSP11011433A/en unknown
-
2013
- 2013-10-24 US US14/061,910 patent/US9120756B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2011149360A (en) | SUBSTITUTED Phenylureas and Phenylamides as Vanilloid Receptor Ligands | |
| HRP20130128T1 (en) | Substituted aromatic carboxamide and urea derivatives as vanilloid receptor ligands | |
| US9096522B2 (en) | N-piperidinyl acetamide derivatives as calcium channel blockers | |
| CA2759951C (en) | Substituted phenylureas and phenylamides as vanilloid receptor ligands | |
| RU2469032C2 (en) | 2-(piperidin-4-yl)-4-phenoxy- or phenylaminopyrimidine derivatives as non nucleoside reverse transcriptase inhibitors | |
| JP2019533694A5 (en) | ||
| US11945796B2 (en) | Substituted pyridine derivatives as SARM1 inhibitors | |
| JP2013517283A5 (en) | ||
| RU2011127232A (en) | APOPTOSIS-INDUCING MEDICINES FOR TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | |
| JP2007514003A5 (en) | ||
| JP2007519754A5 (en) | ||
| JP2014511869A5 (en) | ||
| RU2008144415A (en) | COMPOSITIONS USEFUL AS INHIBITORS OF POTENTIAL DEPENDENT SODIUM CHANNELS | |
| CA2396590A1 (en) | 2-amino-nicotinamide derivatives and their use as vegf-receptor tyrosine kinase inhibitors | |
| NZ614305A (en) | Sulfonamide derivatives as bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases | |
| JP2013517273A5 (en) | ||
| NZ591427A (en) | P38 map kinase inhibitors | |
| US20120258946A1 (en) | Substituted Phenylureas and Phenylamides as Vanilloid Receptor Ligands | |
| NZ537396A (en) | Inhibitors of tyrosine kinases | |
| JP2005524668A5 (en) | ||
| JP2008502614A5 (en) | ||
| JP2005534623A (en) | ERB family inhibitors and methods of treating cancer comprising administering RAF and / or RAS inhibitors | |
| WO2016208602A1 (en) | Pyrazole derivative, or pharmaceutically acceptable salt thereof | |
| CA2669311A1 (en) | Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof | |
| RU2427573C2 (en) | Novel benzimidazole derivatives as vanilloid receptor 1 (vr1) inhibitors |